Pfizer,Genmab: FDA Grants Full Approval For TIVDAK To Treat Recurrent Or Metastatic Cervical Cancer
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – The U.S. Food and Drug Administration approved the supplemental Biologics License
Application or sBLA granting full approval for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or
Application or sBLA granting full approval for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or
:max_bytes(150000):strip_icc():format(jpeg)/Foreclosed-House-Spencer-Platt-Staff-Getty-Images-56a5804c5f9b58b7d0dd3030.jpg "Buying a Foreclosed House: Top 5 Pitfalls")
